Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups

By Nancy Lapid

Aug 9 (Reuters) – Drugmaker Gilead Sciences (GILD.O) plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.

Outside of Africa, where the virus is endemic, new cases have largely occurred among gay and bisexual men. Experts warn that the virus could spread to other populations, especially due to vaccine shortages. The World Health Organization and the United States have declared monkeypox a public health emergency.

The Human Rights Campaign (HRC), GLAAD, the National Black Justice Coalition, and the National Center for Lesbian Rights are each receiving $350,000 from Gilead for public education toward preventing and treating the virus.


The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo/File Photo

Gilead is a leading producer of therapies to treat HIV. The company said it is also evaluating whether any of its treatments or experimental drug candidates could be effective against monkeypox.